Quantum Genomics to present at the 2020 Gordon Conference

Quantum Genomics (Euronext Growth – FR0011648971 – ALQGC, OTCQX – QNNTF), a biopharmaceutical company specializing in developing a new drug class that directly targets the brain to treat resistant hypertension and heart failure, today announced it will share preclinical results of firibastat in heart failure post myocardial ischemia during an oral presentation at the Gordon Research Conference being held from February 8-14, 2020 in Barga, Italy.

Dr. Solene Boitard-Joanne, Pharmacology Department of Quantum Genomics, will present preclinical results of firibastat in mice after myocardial infarction, obtained in collaboration with the INSERM laboratory directed by Dr. Catherine Llorens-Cortès at the Collège de France. The results, published recently in the Journal of Molecular and Cellular Cardiology, demonstrate the efficacy of firibastat in improving cardiac function and preventing the onset of heart failure after a myocardial infarction (Boitard et al, 2019).

Read the press release

Leave a Reply

Your email address will not be published.